In the Presence of other Inherited or Acquired High-risk Situations, the FV Cambridge Mutation May Be an Additional Thrombophilic Risk Factor, through Its Effect on APC Sensitivity

• References

• 1 Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923-7.
• 2 Rodeghiero F, Tosetto A. Activated protein C resistance and Factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-50.
• 3 Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Mannucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-7.
• 4 Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge. A new mutation associated with resistance to activated protein C. Blood 1998; 91: 1140-4.
• 5 Franco RF, Maffei FH, Lourenco D, Morelli V, Thomazini IA, Piccinato CE, Tavella MH, Zago MA. Factor V Arg306→Thr (Factor V Cambridge) and Factor V Arg->306 Gly mutations in venous thrombotic disease. Br J Haematol 1998; 103: 888-90.
• 6 Ames PRJ, Catello T, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies. A crucial role for acquired free protein S deficiency. Thromb Haemost 1996; 76: 190-4.
• 7 Koeleman BPC, Reitsma PH, Allart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
• 8 Margaglione M, D’Andrea G, Grandone E, Brancaccio V, Amoriello A, Di Minno G. Compound heterozygosity (554-589 del, C515-T transition) in the platelet glycoprotein Ib( gene in a patient with a severe bleeding tendency. Thromb Haemost 1999; 81: 486-92.